Skip to main content

Table 2 Tumour response in patients experiencing PLH or PL

From: Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study

 

PLH (n = 84)

PL (n = 86)

p-valuec

p-valued

RECIST version 1.1

mRECIST

RECIST version 1.1

mRECIST

ORRa, n (%)

39 (46.4)

50 (59.5)

26 (30.2)

36 (41.9)

0.030

0.022

95% CI

29.3–54.6

42.7–58.7

22.5–44.7

33.7–57.1

  

Overall responseb, n (%)

    

CR

5 (6.0)

13 (15.5)

1 (1.2)

8 (9.3)

0.092

0.223

PR

34 (40.5)

37 (44.0)

25 (29.1)

28 (32.6)

0.119

0.124

SD

37 (44.0)

24 (28.6)

46 (53.5)

35 (40.7)

0.220

0.098

PD

7 (8.3)

9 (10.7)

11 (12.7)

12 (13.9)

0.346

0.522

NA

1 (1.2)

1 (1.2)

3 (3.5)

3 (3.5)

0.319

0.319

  1. NOTE. RECIST version 1.1 or mRECIST was assessed per independent imaging review
  2. adefined as the proportion of individuals who had a confirmed CR or PR per independent imaging review; binvolved evaluation of the change in tumour burden inside and outside the liver; cthe comparison between the two groups is based on the RECIST version 1.1; d the comparison between the two groups is based on the mRECIST
  3. PLH pembrolizumab plus lenvatinib plus hepatic arterial infusion chemotherapy; PL pembrolizumab plus lenvatinib; RECIST version 1.1 Response Evaluation Criteria in Solid Tumours version 1.1; mRECIST modified RECIST; ORR objective response rate; CI confidence interval; CR complete response; PR partial response; SD stable disease; PD progressive disease; NA not assessable